Using a personalized clinical decision support system for bromdihydrochlorphenylbenzodiazepine dosing in patients with anxiety disorders based on the pharmacogenomic markers
Human Psychopharmacology Clinical and Experimental2018Vol. 33(6), pp. e2677–e2677
Citations Over TimeTop 11% of 2018 papers
M. S. Zastrozhin, Aleksandr S. Sorokin, Tatyana V. Agibalova, Е. А. Гришина, Anastasiya Р. Antonenko, Ilya Nikolaevich Rozochkin, Denis O. Lamoureux, Valentin Yurievich Skryabin, T. Ivanova, Ilya V. Barna, Anna V. Orlova, Альберт Дзастемирович Агузаров, Ludmila M. Savchenko, Evgeny Bryun, Д. А. Сычев
Abstract
Pharmacogenetic-guided personalization of drug dose in patients with alcohol withdrawal syndrome can reduce the risk of undesirable side effects and pharmacoresistance. It allows recommending the use of pharmacogenomic clinical decision support systems for optimizing drug dosage.
Related Papers
- → The future (or lack of future) of personalized prescription in psychiatry(2008)89 cited
- → Implementing Pharmacogenomics Testing: Single Center Experience at Arkansas Children’s Hospital(2021)24 cited
- → Research Highlights: Highlights from the Latest Articles in Transplantation Pharmacogenomics(2012)
- Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients(2013)
- Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients(2013)